Pronunciation: uh-mee-no-kuh-PRO-ik acid
- Tablets 500 mg
- Syrup 250 mg/mL
- Injection 250 mg/mL
Inhibits fibrinolysis to stop bleeding.
Zero order process; absorption rate of 5.2 g/h. C max is about 164 mcg/mL; T max is about 1.2 h.
Vd is about 23.1 L.IV
Vd is about 30 L.
Metabolite is adipic acid.
Renally eliminated. 65% is recovered in the urine as unchanged drug and 11% as the metabolite adipic acid. Renal clearance is 116 mL/min and total body clearance is 169 mL/min. T 1/2 is about 2 h.
3 h for single IV dose.
Indications and Usage
Treatment of excessive bleeding from systemic hyperfibrinolysis and urinary fibrinolysis.
Prevention of recurrence of subarachnoid hemorrhage; management of amegakaryocytic thrombocytopenia; abortion; or prevention of attacks of hereditary angioneurotic edema.
Active intravascular clotting; DIC; administration to newborns.
Dosage and AdministrationAdults
IV/PO 4 to 5 g in first hour; then 1 to 1.25 g/h for 8 h or until bleeding is controlled. Dosage over 30 g/24 h is not recommended.
General AdviceIV infusion
- Dilute as 1 g/50 mL diluent. Compatible diluents include Sterile Water for Injection, normal saline, D5W, and Ringer's solution.
- Infuse dose over 30 min to 1 h.
Store in tightly closed container at room temperature.
Drug InteractionsOral contraceptives or estrogens
May lead to increase in clotting factors, producing state of hypercoagulation.
Laboratory Test InteractionsSerum potassium levels
Serum potassium level may be elevated, especially in impaired renal function.
Bradycardia; hypotension; peripheral ischemia; thrombosis.
Dizziness; headache; delirium; hallucinations; confusion; intracranial hypertension; stroke; syncope.
Tinnitus; decreased vision; watery eyes.
Nausea; diarrhea; abdominal pain; vomiting.
Increased BUN; renal failure.
Agranulocytosis; coagulation disorder; leukopenia; thrombocytopenia.
Dyspnea; nasal congestion; pulmonary embolism.
Injection site reaction; pain and necrosis; myalgia; myositis; myopathy (characterized by muscle weakness, fatigue, elevated creatinine phosphokinase, rhabdomyolysis associated with myoglobinuria and renal failure); edema; allergic and anaphylactic reactions; anaphylaxis; malaise.
Category C .
Safety and efficacy not established.
Upper urinary tract bleeding
Not used in treatment of hematuria of upper UT origin unless possible benefits outweigh risks.
Hypotension, severe acute renal failure.
- Caution patient to avoid sudden position changes to prevent orthostatic hypotension.
- Advise patient to use soft toothbrush or sponge for dental care.
- Instruct patient to report the following symptoms to health care provider: gingival bleeding, epistaxis, hematuria, skin changes (eg, ecchymosis, petechiae), difficulty in urination, reddish-brown urine, chest or leg pain, or difficulty breathing.
Copyright © 2009 Wolters Kluwer Health.